Fisher & Paykel Healthcare Corporation Limited advises that all resolutions put to the company’s annual shareholders’ meeting held today were passed. The seven resolutions were: Resolution 1: To re-elect Pip Greenwood as a Director. Resolution 2: To re-elect Geraldine McBride as a Director. Resolution 3: To authorise the Directors to fix the fees and expenses of the company’s auditor. Resolution 4: That the maximum aggregate annual remuneration payable to non-executive Directors be increased by NZ$405,000 from NZ$1,050,000 to NZ$1,455,000 (plus GST as appropriate). Resolution 5: To approve the issue of share rights to Lewis Gradon as set out in the Notice of Annual Shareholders’ Meeting 2020. Resolution 6: To approve the issue of options to Lewis Gradon as set out in the Notice of Annual Shareholders’ Meeting 2020. Resolution 7: To approve the 2019 Performance Share Rights Plan Rules – North American Plan and the 2019 Share Option Plan Rules – North American Plan. All resolutions were decided by poll. The details of the total number of votes cast in person or by proxy on the polls were as follows:
Resolution
Votes For
%
Votes Against
Total Votes Cast
Abstain
Resolution 1: Re-election of Pip Greenwood
402,504,990
99.76
955,372
404,362,554
902,192
Resolution 2: Re-election of Geraldine McBride
403,086,593
99.94
239,507
1,036,454
Resolution 3: Authorise Directors to fix fees and expenses of auditor
399,755,938
99.12
3,562,147
1,044,469
Resolution 4: To increase the maximum aggregate annual remuneration payable to non-executive Directors
292,256,515
72.74
109,553,169
403,025,719
1,216,035
Resolution 5: Issue of share rights to Lewis Gradon
363,413,701
90.13
39,776,318
1,172,535
Resolution 6: Issue of options to Lewis Gradon
363,712,724
90.19
39,568,515
1,081,315
Resolution 7: Approve 2019 Share Rights Plan Rules - North American Plan and 2019 Share Option Plan Rules – North American Plan
397,115,687
98.49
6,087,732
1,159,135
Authorised by Marcus Driller, VP Corporate & Company Secretary Contact: Marcus Driller, VP – Corporate and Company Secretary on +64 9 574 0110. For more information about the company visit our website www.fphcare.com.
2020 Annual Shareholders’ Meeting Results
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
We value your privacy. Our websites and applications use cookies to function properly and securely.